Analysts/Institutional Investor Meet/Con. Call Updates

Ref: Akums/Exchange/2026-27/44 August 13, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 544222 Symbol: AKUMS Sub: Transcript of the Investors/Analysts Conference Call for the unaudited financial results of Q1 FY 27 Respected Sir/Ma’am, Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the transcript of investors/analyst conference call held on Monday, August 10, 2026 at 12:00 P.M. (IST) for un-audited financial results of Akums Drugs and Pharmaceuticals Limited (“the Company”) for the quarter ended June 30 2026. The said transcript will also be available on the Company’s website at https://www.akums.in/investors/investors-meet/ This is for your kind information and records. Thanking You For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl.: As above “Akums Drugs & Pharmaceuticals Limited 1QFY27 Earnings Conference Call” August 10, 2026 MANAGEMENT: MR. SANJEEV JAIN – MANAGING DIRECTOR – AKUMS DRUGS & PHARMACEUTICALS LIMITED MR. SANDEEP JAIN – MANAGING DIRECTOR – AKUMS DRUGS & PHARMACEUTICALS LIMITED MR. SUMEET SOOD – CHIEF FINANCIAL OFFICER – AKUMS DRUGS & PHARMACEUTICALS LIMITED MR. SAHIL MAHESHWARI – HEAD, STRATEGY – AKUMS DRUGS & PHARMACEUTICALS LIMITED MR. ANKIT JAIN – HEAD, INVESTOR RELATIONS – AKUMS DRUGS & PHARMACEUTICALS LIMITED MODERATOR: MR. UMESH LADDHA – AMBIT CAPITAL Page 1 of 12 Akums Drugs & Pharmaceuticals Limited August 10, 2026 Moderator: Good day, ladies and gentlemen. Welcome to the Akums Drugs & Pharmaceuticals 1QFY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star, then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Umesh Laddha. Thank you, and over to you, sir. Umesh Laddha: Good afternoon, everyone. And on behalf of Ambit Capital, I thank the management of Akums Drugs & Pharmaceuticals for the opportunity to host their 1QFY27 earnings conference call. Joining from the management today, we have Mr. Sanjeev Jain, Managing Director; Mr. Sandeep Jain, Managing Director; Mr. Sumeet Sood, CFO; and Mr. Sahil Maheshwari, Head Strategy. We now begin with opening remarks from the management, post which the forum will be open for question-and-answer session. Thank you, and over to you, Ankit, sir. Ankit Jain: Thank you, Umesh, for the introduction. Good afternoon, everyone, and welcome to Akums' 1QFY27 earnings call. I am Ankit Jain, and I head Investor Relations at Akums Drugs & Pharmaceuticals Limited. I will commence with a standard disclaimer that any discussion on today's call might include certain forward-looking statements, which are predictions or projections of future events. Our business faces several risks and uncertainties that could cause our results to differ materially from what is expressed or implied in such statements. At Akums, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. I hope you would have had the opportunity to go through our financial reviews and reviewed our investor presentation that was shared on Saturday. I would now like to hand over to our Managing Director, Mr. Sandeep Jain, to discuss our performance. Thank you. Sandeep Jain: Namaste, everyone, and thank you for joining us today for our 1QFY27 earnings call. With 1QFY27, we have begun FY27 on a strong and encouraging note. We registered a healthy revenue growth of over 13% with EBITDA increasing by more than 30%. The growth was primarily led by CDMO segment characterized by double-digit volume growth along with improvement in API prices. The consistent performance of CDMO showcases healthy demand environment as well as our clients' trust in Akums as the preferred manufacturing partners. Marketing segments, domestic as well as exports saw muted quarterly performances with multiple initiatives underway. We are confident of these segments returning to growth path in coming quarters. Our API and trade generics segments performed in line with prior guidance with Zambia order to likely reflect during current financial year. Akums is well placed to deliver a robust operating performance during FY27. Page 2 of 12 Akums Drugs & Pharmaceuticals Limited August 10, 2026 On 23rd of July, we announced the acquisition of Oriflame India's manufacturing business. The transaction covers two manufacturing facilities, one at Roorkee, Uttarakhand and other one at Noida, Uttar Pradesh, along with a leased warehouse situated at Noida, Uttar Pradesh. With the acquisition, we expand our manufacturing footprint in skin care cosmetics and wellness products. This is in line with our strategy of tapping into niche formulations to improve our positions among existing as well as prospective clients and augment our margins. Coming to operating performances for our quarter. CDMO once again delivered a healthy top- line growth of over 18%, aided by both volume growth and improvement in API prices. API segment continued on its journey towards becoming EBITDA positive as higher share of non- cepha products led to better gross margin. The trade generics segment remained EBITDA positive during the quarter. Akumentis, our domestic branded formulations segment, restarted its growth journey with a healthy 7% revenue growth during the quarter. Margins were impacted due to an increase in employee strength. We expected improved performance from the segment from quarter 3 onwards. Our international branded formulation business had a muted quarter, but is expected to return to growth as we remain confident in the structural attractiveness of our chosen geographies. I shall now request our CFO, Mr. Sumeet Sood, to take you through the detailed financials for the quarter. Over to you, Mr. Sumeet. Sumeet Sood: Thank you, sir. Thank you, Sandeep-ji. Good afternoon, everyone. I would now take you through the financial highlights for the quarter ended 30th June 2026. Our operating revenue stood at INR1,167 crores, an increase of 13.9% year-on-year. Quarter 1 FY26, the revenue was INR1,024 crores and increasing 0.8% quarter-on-quarter. Quarter 4 FY26, our revenue was INR1,158 crores. The operating EBITDA for the quarter was INR175 crores, an increase of 35.4% year-on-year. Quarter 1 FY26, our EBITDA was INR129 crores and 15.1% quarter-on-quarter. Q4 FY26, our EBITDA was INR152 crores. Margins were robust at 15%, improving 238 basis points year-on- year. Quarter 1 FY26, we were at 12.6%, and 187 basis points quarter-on-quarter or Q4 FY26, we were at 13.1%. EBITDA, including other income, stood at INR205 crores, increasing 31.7% year-on-year. Quarter 1 FY26, we were at INR156 crores, and increasing 9.6% quarter-on-quarter. Quarter 4 FY26, we were at INR187 crores. EBITDA margins stood at 17.1%, increasing 231 basis points Year-on-year, Q1 FY26, we were at 14.8% and quarter-on-quarter Q4 '26, we were at 15.7%. The PAT of the company stood at INR101 crores, an increase of 56.1% year-on-year. We were at INR65 crores in quarter 1 FY26, and increasing 24.1% quarter-on-quarter. Q4 '26, we stood at INR81 crores. If we were to look at the various segments and their performance, if we start with the CDMO, the revenue stood at INR964 crores, increase of 18.6% year-on-year, we were at INR813 crores Q1 FY26, an increase of 1.3% quarter-on-quarter, Q4 FY26, we were at INR952 crore [Showing first 8,000 characters — download PDF for full document]